BRAF and malignant colon neoplasm: A colon cancer cell line with a BRAF V600E mutation was shown to escape vemurafenib inhibition by activating the epithelial growth factor receptor (EGFR); however, treatment of these cells with vemurafenib and an EGFR inhibitor prevented vemurafenib resistance and induced apoptosis [15].